Cancer Drug Alzheimers

February 11, 2012 by staff 

Cancer Drug Alzheimers, A widely available cancer drug has shown remarkable success in reversing Alzheimer’s disease in mice, raising hope of a breakthrough against incurable dementia in humans, US researchers said Thursday.
Mice treated with the drug, known as bexarotene, became rapidly smarter and the plaque in their brains that was causing Alzheimer’s started to disappear within hours, said the research in the US journal Science.

“We were shocked and amazed,” lead author Gary Landreth, a professor in the Department of Neurosciences at Case Western Reserve University School of Medicine in Ohio, told AFP.

“Things like this had never, ever been seen before,” he said.

The drug works by boosting levels of a protein, Apolipoprotein E (ApoE), that helps clear amyloid plaque buildup in the brain, a key hallmark of Alzheimer’s disease.

“Think of this as a garbage disposal,” Landreth said.

“When we are young and healthy, all of us can basically get rid of this (amyloid) and degrade it and grind it into small bits and it gets cleared.

“Many of us will be unable to do this as efficiently as we age. And this is associated with mental decline or cognitive impairment.”

Six hours after mice got the drug, which works through the liver to boost retinoid X receptors (RXR), stimulating production of ApoE in the brain, soluble amyloid levels fell 25 percent, ultimately reaching a 75 percent drop.

The effect lasted up to three days, said the study.

Soon after taking the drug, mice began performing better in tests, showing that they were able to remember things again, were more social and were able to smell again, a sense that is commonly lost in Alzheimer’s.

Also, unlike normal mice, Alzheimer’s mice will not usually build nests if given tissue paper in their cage, as if they have forgotten to associate paper with the opportunity to nest.

But 72 hours after treatment, the Alzheimer’s mice began to build nests again.

“They are not great nests but they are nests nonetheless,” added Landreth, suggesting that if the drug can be shown to work in humans it might be best targeted at people in the early stages of the disease.

Report to Team

Please feel free to send if you have any questions regarding this post , you can contact on

Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.


Comments are closed.